Age
Item
1. patients aged 20 years or over
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
2. patients who were fully informed of the study beforehand and signed the informed consent to participate in the study.
boolean
C0021430 (UMLS CUI [1])
Life Expectancy
Item
3. patients who are expected to live more than 12 weeks.
boolean
C0023671 (UMLS CUI [1])
Liver carcinoma Biopsy | Liver carcinoma Diagnostic Imaging | Liver carcinoma CT | Liver carcinoma MRI
Item
4. patients diagnosed with typical hcc by biopsy,cytology, or diagnostic imaging such as dynamic ct(mri).typical hcc is defined by aasld criteria.
boolean
C2239176 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C2239176 (UMLS CUI [2,1])
C0011923 (UMLS CUI [2,2])
C2239176 (UMLS CUI [3,1])
C0040405 (UMLS CUI [3,2])
C2239176 (UMLS CUI [4,1])
C0024485 (UMLS CUI [4,2])
Hepatectomy Unsuccessful | Radiofrequency ablation Unsuccessful
Item
5. patients in whom complete resection of the tumor by hepatectomy or complete tumor necrosis by local tumor necrosis therapy(rfa) cannot be expected to succeed.
boolean
C0019144 (UMLS CUI [1,1])
C1272705 (UMLS CUI [1,2])
C0850292 (UMLS CUI [2,1])
C1272705 (UMLS CUI [2,2])
Transarterial Chemoembolization Liver tumors | Tumor Diameter Maximum | Nodules Quantity Maximum
Item
6. patients with tumors which are confirmed to the liver and can be treated by tace(the maximum diameter equal to or less than 10cm,and the maximum number of nodule equal to or less than 10).
boolean
C3539919 (UMLS CUI [1,1])
C0023903 (UMLS CUI [1,2])
C0027651 (UMLS CUI [2,1])
C1301886 (UMLS CUI [2,2])
C0806909 (UMLS CUI [2,3])
C0028259 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0806909 (UMLS CUI [3,3])
Target Lesion Measurable
Item
7. patients with viable and measurable target lesion.
boolean
C2986546 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
Transarterial Chemoembolization Absent | Transarterial Chemoembolization Quantity
Item
8. patients with no or one history of tace therapy.
boolean
C3539919 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C3539919 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
ECOG performance status
Item
9. patients with an ecog ps(performance status) score of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Child-Pugh Classification
Item
10. patients with child-pugh class a.
boolean
C4050412 (UMLS CUI [1])
Laboratory Results Fulfill Criteria
Item
11. patients with laboratory values that meet the following criteria:
boolean
C1254595 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C0243161 (UMLS CUI [1,3])
Hemoglobin measurement
Item
1. hemoglobin ≥ 8.5 g/dl
boolean
C0518015 (UMLS CUI [1])
Granulocyte count
Item
2. granulocytes ≥ 1500/mm3
boolean
C0857490 (UMLS CUI [1])
Platelet Count measurement
Item
3. platelet count ≥ 50,000 /mm3
boolean
C0032181 (UMLS CUI [1])
Serum total bilirubin measurement
Item
4. total serum bilirubin ≤ 3 mg/dl
boolean
C1278039 (UMLS CUI [1])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
5. ast and alt ≤ 6 times upper limits of normal
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
Creatinine measurement, serum
Item
6. serum creatinine ≤ 1.5 times upper limits of normal
boolean
C0201976 (UMLS CUI [1])
Malignant Neoplasms
Item
1. history of malignant tumor, excluding the following cases:
boolean
C0006826 (UMLS CUI [1])
Exception Curative treatment Early stage cancer | Exception Low Risk Recurrent tumor | Exception Carcinoma in situ of uterine cervix | Exception Basal cell carcinoma | Exception Superficial carcinoma of urinary bladder | Exception Early gastric cancer
Item
1. curatively treated early stage cancer with a low risk of recurrence ,such as carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumor, and early gastric cancer.
boolean
C1705847 (UMLS CUI [1,1])
C1273390 (UMLS CUI [1,2])
C1517886 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C3538919 (UMLS CUI [2,2])
C0521158 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0007117 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C1336527 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0349530 (UMLS CUI [6,2])
Exception Curative treatment Malignant Neoplasm | Exception Recurrent tumor Absent
Item
2. malignant tumor that was curatively treated more than 3 years prior to study entry and has not recurred since then
boolean
C1705847 (UMLS CUI [1,1])
C1273390 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0521158 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Heart Disease | Criteria Any Fulfill
Item
2. cardiac disease that meet any of the following criteria:
boolean
C0018799 (UMLS CUI [1])
C0243161 (UMLS CUI [2,1])
C1552551 (UMLS CUI [2,2])
C1550543 (UMLS CUI [2,3])
Congestive heart failure New York Heart Association Classification
Item
1. nyha class iii or higher congestive heart failure
boolean
C0018802 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Coronary Artery Disease Symptomatic | Myocardial Infarction
Item
2. history of symptomatic coronary artery disease or myocardial infarction within 6 months before enrollment
boolean
C1956346 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0027051 (UMLS CUI [2])
Cardiac Arrhythmia Requirement Anti-Arrhythmia Agents | Adrenergic beta-1 Receptor Antagonists Required | Digoxin Required
Item
3. arrhythmia requiring control by antiarrhythmic drugs such as beta-blockers or digoxin
boolean
C0003811 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0003195 (UMLS CUI [1,3])
C0304516 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0012265 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
Communicable Disease Serious | Exception Hepatitis B | Exception Hepatitis C
Item
3. serious and active infection, except for hbv and hcv
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0019163 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0019196 (UMLS CUI [3,2])
HIV Infection
Item
4. history of hiv infection
boolean
C0019693 (UMLS CUI [1])
Hemodialysis
Item
5. renal dialysis
boolean
C0019004 (UMLS CUI [1])
Tumor Diffuse Lesion
Item
6. diffuse tumor lesion
boolean
C0027651 (UMLS CUI [1,1])
C1707743 (UMLS CUI [1,2])
Neoplasm Metastasis Extrahepatic
Item
7. extrahepatic metastasis
boolean
C0027627 (UMLS CUI [1,1])
C1517058 (UMLS CUI [1,2])
Vascular Invasion
Item
8. vascular invasion
boolean
C0521157 (UMLS CUI [1])
Neoplasms, Intracranial
Item
9. intracranial tumor
boolean
C1527390 (UMLS CUI [1])
Hepatic Encephalopathy Pre-existing | Hepatic Encephalopathy
Item
10. preexisting or history of hepatic encephalopathy
boolean
C0019151 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C0019151 (UMLS CUI [2])
Ascites Uncontrolled | Pleural effusion Uncontrolled
Item
11. clinically uncontrolled ascites or pleural effusion
boolean
C0003962 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0032227 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Gastrointestinal Hemorrhage Severe
Item
12. clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment
boolean
C0017181 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Esophageal Varices | Gastric Varices | High risk of bleeding
Item
13. esophageal and/or gastric varices which has high risk of bleeding
boolean
C0014867 (UMLS CUI [1])
C0017145 (UMLS CUI [2])
C4039184 (UMLS CUI [3])
Thrombosis | Embolism
Item
14. history of thrombosis and/or embolism within 6 months of the start of treatment
boolean
C0040053 (UMLS CUI [1])
C0013922 (UMLS CUI [2])
Therapy Specified Any
Item
15. history of receiving any of the following therapies:
boolean
C0087111 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
Systemic Chemotherapy Advanced Adult Hepatocellular Carcinoma | sorafenib
Item
1. systemic chemotherapy for advanced hcc(including sorafenib therapy)
boolean
C1883256 (UMLS CUI [1,1])
C1706732 (UMLS CUI [1,2])
C1516119 (UMLS CUI [2])
Local Therapy | Radiofrequency ablation | Transarterial Chemoembolization | Hepatic arterial infusion
Item
2. local therapy, such as radiofrequency ablation, tace, or hepatic arterial infusion within 3 months of the start of treatment
boolean
C1517925 (UMLS CUI [1])
C0850292 (UMLS CUI [2])
C3539919 (UMLS CUI [3])
C1134564 (UMLS CUI [4])
CYP3A4 Inducers
Item
3. current treatment with cyp3a4 inducing agents
boolean
C3850041 (UMLS CUI [1])
Surgery invasive
Item
4. invasive surgery within 4 weeks of the start of treatment
boolean
C0543467 (UMLS CUI [1,1])
C0348025 (UMLS CUI [1,2])
Transplantation, Homologous
Item
5. history of allogenic transplantation
boolean
C0040739 (UMLS CUI [1])
Bone Marrow Transplantation | Hemopoietic stem cell transplant
Item
6. history of bone marrow transplant or haemopoietic stem cell transplant within 4 weeks of the start of this study
boolean
C0005961 (UMLS CUI [1])
C0472699 (UMLS CUI [2])
Lacking Able to swallow Oral medication
Item
16. unable to take oral medications
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0175795 (UMLS CUI [1,3])
Gastrointestinal problem Affecting Absorption Investigational New Drugs | Gastrointestinal problem Affecting Pharmacokinetics Investigational New Drugs
Item
17. gastrointestinal problems that may affect absorption or pharmacokinetics of the study drugs
boolean
C0017187 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0237442 (UMLS CUI [1,3])
C0013230 (UMLS CUI [1,4])
C0017187 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0031327 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])
Drugs Affecting Absorption Investigational New Drugs | Drugs Affecting Pharmacokinetics Investigational New Drugs
Item
18. use of drugs that may affect absorption or pharmacokinetics of the study drugs
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0237442 (UMLS CUI [1,3])
C0013230 (UMLS CUI [1,4])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0031327 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])
Comorbidity Affecting Evaluation Investigational New Drugs
Item
19. concurrent disease or disability that may affect evaluation of the effects of the study drugs
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C1261322 (UMLS CUI [1,3])
C0013230 (UMLS CUI [1,4])
Study Subject Participation Status | Clinical Trial
Item
20. enrollment in another study within 4 weeks of study entry
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2])
Pregnancy | Breast Feeding | Possible pregnancy | Pregnancy, Planned
Item
21. female patients who are pregnant, lactating, possibly pregnant, or planning to become pregnant
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0425965 (UMLS CUI [3])
C0032992 (UMLS CUI [4])
Risk Allergic Reaction Investigational New Drugs
Item
22. risk of allergic reactions to the study drugs
boolean
C0035647 (UMLS CUI [1,1])
C1527304 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
Drug abuse Interferes with Study Subject Participation Status | Drug abuse Interferes with Evaluation Research results | Physical handicap problem | Mental problem | Social Problem
Item
23. drug abuse or other physical, psychological , or social problems that may interfere with the participation in the study or evaluation of study results
boolean
C0013146 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0013146 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C1261322 (UMLS CUI [2,3])
C0683954 (UMLS CUI [2,4])
C0421228 (UMLS CUI [3])
C0848067 (UMLS CUI [4])
C0037431 (UMLS CUI [5])
Condition At risk Patient safety | Condition At risk Protocol Compliance
Item
24. any condition that could jeopardize the safety of the patient or their compliance in the study
boolean
C0348080 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C1113679 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])